SG11201808797XA - T cell receptors - Google Patents
T cell receptorsInfo
- Publication number
- SG11201808797XA SG11201808797XA SG11201808797XA SG11201808797XA SG11201808797XA SG 11201808797X A SG11201808797X A SG 11201808797XA SG 11201808797X A SG11201808797X A SG 11201808797XA SG 11201808797X A SG11201808797X A SG 11201808797XA SG 11201808797X A SG11201808797X A SG 11201808797XA
- Authority
- SG
- Singapore
- Prior art keywords
- park
- international
- milton
- immunocore limited
- oxfordshire
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 abstract 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000012737 microarray-based gene expression Methods 0.000 abstract 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 2
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 abstract 1
- 108010012015 GVYDGREHTV Proteins 0.000 abstract 1
- 102000011786 HLA-A Antigens Human genes 0.000 abstract 1
- 108010075704 HLA-A Antigens Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000001069 Raman spectroscopy Methods 0.000 abstract 1
- 241000388430 Tara Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111100111011011101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number ..... .....!;,,, (43) International Publication Date WO 2017/175006 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: KILBURN & STRODE LLP; 20 Red Lion Street, CO7K 14/725 (2006.01) London, Greater London, WC1R 4PJ (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2017/050985 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 7 April 2017 (07.04.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (30) Priority Data: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 1606009.7 8 April 2016 (08.04.2016) GB RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant: IMMUNOCORE LIMITED [GB/GB]; 101 ZA, ZM, ZW. Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: HAYES, Conor; c/o Immunocore Limited, 101 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Park Drive, Milton Park, Abingdon Oxfordshire OX14 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 4RY (GB). HIBBERT, Linda; c/o Immunocore Limited, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 4RY (GB). LIDDY, Nathaniel; c/o Immunocore Limited, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 4RY (GB). MAHON, Tara; c/o Immunocore Limited, 101 GW, KM, ML, MR, NE, SN, TD, TG). — _ Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY RAMAN, Marine; Immunocore Limited, Published: = (GB). c/o 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 — with international search report (Art. 21(3)) 4RY (GB). = = = = = = = = = = = = 1-1 ,tD 0 0 1 1 in IN ,—, IN 1-1 (54) Title: T CELL RECEPTORS 0 ei (57) : The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV en. ) (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the al- pha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606009 | 2016-04-08 | ||
| PCT/GB2017/050985 WO2017175006A1 (en) | 2016-04-08 | 2017-04-07 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808797XA true SG11201808797XA (en) | 2018-11-29 |
Family
ID=58548761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808797XA SG11201808797XA (en) | 2016-04-08 | 2017-04-07 | T cell receptors |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11505590B2 (en) |
| EP (2) | EP3440105B1 (en) |
| JP (1) | JP7254519B2 (en) |
| KR (1) | KR102473964B1 (en) |
| CN (1) | CN109563148B (en) |
| AU (2) | AU2017246693B2 (en) |
| BR (1) | BR112018070741A2 (en) |
| CA (1) | CA3020214A1 (en) |
| CL (1) | CL2018002859A1 (en) |
| CO (1) | CO2018011972A2 (en) |
| CR (1) | CR20180531A (en) |
| DK (1) | DK3440105T3 (en) |
| ES (1) | ES2914648T3 (en) |
| HR (1) | HRP20220865T1 (en) |
| HU (1) | HUE059159T2 (en) |
| IL (2) | IL262144B2 (en) |
| LT (1) | LT3440105T (en) |
| MA (1) | MA44608B1 (en) |
| MD (1) | MD3440105T2 (en) |
| MX (1) | MX2018012318A (en) |
| MY (1) | MY198621A (en) |
| PE (1) | PE20190335A1 (en) |
| PH (1) | PH12018502158A1 (en) |
| PL (1) | PL3440105T3 (en) |
| PT (1) | PT3440105T (en) |
| RS (1) | RS63371B1 (en) |
| SG (1) | SG11201808797XA (en) |
| SI (1) | SI3440105T1 (en) |
| WO (1) | WO2017175006A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017174822A1 (en) * | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
| WO2017174823A1 (en) * | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| CN112585276A (en) * | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | Methods of producing cells expressing recombinant receptors and related compositions |
| CN113645953A (en) | 2019-01-17 | 2021-11-12 | 英美偌科有限公司 | Preparation |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| US20220324939A1 (en) * | 2019-06-18 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | Mage-a4 t cell receptors and methods of use thereof |
| JP7295283B2 (en) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | FLT3L-FC fusion proteins and methods of use |
| JP7296467B2 (en) | 2019-12-18 | 2023-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Antibodies that bind to HLA-A2/MAGE-A4 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| AU2021275049A1 (en) * | 2020-05-19 | 2022-12-22 | Amgen Inc. | MAGEB2 binding constructs |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| WO2022190009A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| TW202328212A (en) | 2021-12-01 | 2023-07-16 | 英商英美偌科有限公司 | Treatment of mage-a4 positive cancer |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| TW202346277A (en) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros zinc finger family degraders and uses thereof |
| TW202400138A (en) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d modulating compounds |
| CN117106060A (en) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | High-affinity T cell receptor for recognizing MAGE and application thereof |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| US20240092859A1 (en) | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
| WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0977886A4 (en) | 1997-03-07 | 2002-10-23 | Sunol Molecular Corp | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| JP2001519143A (en) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | Soluble single-chain T cell receptor protein |
| AU5992999A (en) | 1998-10-02 | 2000-04-26 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| WO2001048145A2 (en) | 1999-12-06 | 2001-07-05 | Board Of Trustees Of The University Of Illinois | High affinity tcr proteins and methods |
| AU2001232204A1 (en) | 2000-02-22 | 2001-09-03 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| EP1421115B1 (en) | 2001-08-31 | 2005-03-02 | Avidex Limited | Soluble t cell receptor |
| WO2004023973A2 (en) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| EP2301964A1 (en) | 2005-04-01 | 2011-03-30 | Immunocore Ltd. | High affinity HIV T cell receptors |
| CN101287831B (en) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T-cell receptor and nucleic acid encoding the receptor |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| EP2755997B1 (en) | 2011-09-15 | 2018-07-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| KR20140108520A (en) | 2011-10-14 | 2014-09-11 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ANTIBODIES TO CD1d |
| IL305550A (en) | 2011-10-28 | 2023-10-01 | Regeneron Pharma | Genetically modified t cell receptor mice |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| PL2951202T3 (en) * | 2013-01-29 | 2020-09-21 | Max Delbrück Centrum für Molekulare Medizin (MDC) | High avidity binding molecules recognizing mage-a1 |
| WO2014160030A2 (en) | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
| EP3166647A4 (en) | 2014-07-09 | 2018-02-14 | The Regents of the University of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
| JP6712261B2 (en) | 2014-08-04 | 2020-06-24 | フレッド ハッチンソン キャンサー リサーチ センター | WT-1 specific T cell immunotherapy |
| MY188432A (en) | 2015-04-13 | 2021-12-08 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| CN116731156A (en) | 2016-03-16 | 2023-09-12 | 伊玛提克斯生物技术有限公司 | Transfected T cells and T cell receptors for cancer immunotherapy |
| JP7034934B2 (en) | 2016-04-01 | 2022-03-14 | カイト ファーマ インコーポレイテッド | Chimeric antigen and T cell receptor, and how to use |
-
2017
- 2017-04-07 MX MX2018012318A patent/MX2018012318A/en unknown
- 2017-04-07 HU HUE17717845A patent/HUE059159T2/en unknown
- 2017-04-07 SG SG11201808797XA patent/SG11201808797XA/en unknown
- 2017-04-07 EP EP17717845.6A patent/EP3440105B1/en active Active
- 2017-04-07 LT LTEPPCT/GB2017/050985T patent/LT3440105T/en unknown
- 2017-04-07 ES ES17717845T patent/ES2914648T3/en active Active
- 2017-04-07 RS RS20220652A patent/RS63371B1/en unknown
- 2017-04-07 IL IL262144A patent/IL262144B2/en unknown
- 2017-04-07 PL PL17717845.6T patent/PL3440105T3/en unknown
- 2017-04-07 HR HRP20220865TT patent/HRP20220865T1/en unknown
- 2017-04-07 MY MYPI2018001690A patent/MY198621A/en unknown
- 2017-04-07 IL IL308831A patent/IL308831A/en unknown
- 2017-04-07 SI SI201731151T patent/SI3440105T1/en unknown
- 2017-04-07 JP JP2018552859A patent/JP7254519B2/en active Active
- 2017-04-07 DK DK17717845.6T patent/DK3440105T3/en active
- 2017-04-07 WO PCT/GB2017/050985 patent/WO2017175006A1/en active Application Filing
- 2017-04-07 AU AU2017246693A patent/AU2017246693B2/en active Active
- 2017-04-07 KR KR1020187032374A patent/KR102473964B1/en active IP Right Grant
- 2017-04-07 PT PT177178456T patent/PT3440105T/en unknown
- 2017-04-07 CR CR20180531A patent/CR20180531A/en unknown
- 2017-04-07 MD MDE20190184T patent/MD3440105T2/en unknown
- 2017-04-07 EP EP21211000.1A patent/EP4023668A1/en active Pending
- 2017-04-07 CN CN201780035758.0A patent/CN109563148B/en active Active
- 2017-04-07 BR BR112018070741-4A patent/BR112018070741A2/en unknown
- 2017-04-07 CA CA3020214A patent/CA3020214A1/en active Pending
- 2017-04-07 US US16/092,174 patent/US11505590B2/en active Active
- 2017-04-07 PE PE2018001971A patent/PE20190335A1/en unknown
- 2017-04-07 MA MA44608A patent/MA44608B1/en unknown
-
2018
- 2018-10-08 CL CL2018002859A patent/CL2018002859A1/en unknown
- 2018-10-08 PH PH12018502158A patent/PH12018502158A1/en unknown
- 2018-11-02 CO CONC2018/0011972A patent/CO2018011972A2/en unknown
-
2022
- 2022-10-13 US US18/046,408 patent/US20230322895A1/en active Pending
- 2022-10-19 AU AU2022256131A patent/AU2022256131A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808797XA (en) | T cell receptors | |
| SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201808675VA (en) | Method and kit for the generation of dna libraries for massively parallel sequencing | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201901172QA (en) | A method for manufacturing a fuel component | |
| SG11201809716VA (en) | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII | |
| SG11201809473QA (en) | Humanized anti-basigin antibodies and the use thereof | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof |